- Conditions
- Perennial Allergic Rhinitis (PAR)
- Interventions
- LY3650150, Placebo, Standard therapy for INCS
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 26
- States / cities
- Huntington Beach, California • Inglewood, California • Laguna Niguel, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 35
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Asthma
- Interventions
- lebrikizumab, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 70
- States / cities
- Pell City, Alabama • Scottsdale, Arizona • Tucson, Arizona + 63 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo, Topical Corticosteroid
- Biological · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 43
- States / cities
- Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Northridge, California + 17 more
- Conditions
- Prurigo Nodularis (PN)
- Interventions
- Lebrikizumab
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 54 more
- Conditions
- Psoriasis, Atopic Dermatitis
- Interventions
- In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
- Device · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab Pen
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Healthy Volunteer
- Interventions
- lebrikizumab, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo, TCS Cream
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 13 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo
- Biological · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 40
- States / cities
- Scottsdale, Arizona • Rogers, Arkansas • Bakersfield, California + 35 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Interventions
- LY3650150, Placebo, Standard therapy for INCS
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 160
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 58
- States / cities
- Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
- Conditions
- Atopic Hand and Foot Dermatitis
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Fountain Valley, California • Los Angeles, California • Hollywood, Florida + 10 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 29 more
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Montelukast, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 30 more
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Lebrikizumab, Pirfenidone, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo
- Biological · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 30
- States / cities
- Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Long Beach, California • Miami, Florida + 6 more
- Conditions
- Healthy Volunteer
- Interventions
- Lebrikizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 4
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more